Impact of baseline beta-blocker use on inotrope response and clinical outcomes in cardiogenic shock: a subgroup analysis of the DOREMI trial.

Pietro Di SantoRebecca MathewRichard G JungTrevor SimardStephanie SkanesBrennan MaoF Daniel RamirezJeffrey A MarbachOmar Abdel-RazekPouya MotazedianSimon ParlowKevin E BoczarGianni D'EgidioSteven HawkenJordan BernickGeorge A WellsAlexander DickDerek Y SoChristopher GloverJuan J RussoCaroline McGuintyBenjamin Hibbertnull null

Published in: Critical care (London, England) (2021)

BB therapy in the 24 h preceding the development of CS did not negatively influence clinical outcomes or hemodynamic parameters. On the contrary, BB use was associated with fewer deaths in the early resuscitation period, suggesting a paradoxically protective effect in patients with CS. Trial registration ClinicalTrials.gov Identifier: NCT03207165.

Keyphrases

phase iii
study protocol
growth factor
clinical trial
phase ii
cardiac arrest
open label
randomized controlled trial
double blind
mesenchymal stem cells
cell therapy
angiotensin ii